Skip to main content

Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month

The remarks come as U.S. health insurers balk at the extreme cost of Wegovy and other obesity drugs and drop them from their plans.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.